CHMMF vs VRTX: Which Stock is Better?
Side-by-side comparison of Chimeric Therapeutics Limited and Vertex Pharmaceuticals Inc in 2026
CHMMF
Chimeric Therapeutics Limited
$0.00
VRTX
Vertex Pharmaceuticals Inc
$441.20
Key Metrics Comparison
| Metric | CHMMF | VRTX | Winner |
|---|---|---|---|
| Market Cap | $4.42M | $112.22B | VRTX |
| P/E Ratio | N/A | 28.82 | VRTX |
| EPS (TTM) | $N/A | $15.31 | VRTX |
| Revenue Growth | -0.5% | 0.1% | VRTX |
| Gross Margin | 91.3% | 53.7% | CHMMF |
Analyze CHMMF
Full quant analysis
Analyze VRTX
Full quant analysis
Analyze Each Stock
Frequently Asked Questions
Is CHMMF or VRTX a better investment?
Comparing CHMMF and VRTX: Chimeric Therapeutics Limited has a market cap of $4.42M while Vertex Pharmaceuticals Inc has $112.22B. Both companies have their strengths - use our detailed metrics comparison to make an informed decision.
What is the difference between CHMMF and VRTX?
CHMMF (Chimeric Therapeutics Limited) and VRTX (Vertex Pharmaceuticals Inc) differ in valuation, growth rates, and profitability metrics. Our comparison shows which company leads in each category.
Which stock has better value: CHMMF or VRTX?
Based on P/E ratios, compare detailed valuation metrics on our dashboard.
Which is growing faster: CHMMF or VRTX?
VRTX has higher revenue growth at 0.1% vs -0.5% for CHMMF.
Which company is more profitable: CHMMF or VRTX?
Chimeric Therapeutics Limited (CHMMF) has higher gross margins at 91.3% compared to 53.7% for VRTX.
Which is the larger company: CHMMF or VRTX?
Vertex Pharmaceuticals Inc (VRTX) is larger with a market cap of $112.22B compared to $4.42M for CHMMF.
Should I buy CHMMF or VRTX in 2026?
Both CHMMF and VRTX have investment merit. CHMMF trades at $0.00 while VRTX trades at $441.20. Consider your investment goals, risk tolerance, and portfolio diversification before deciding. Our AI analysis tools can provide personalized insights.
What are the key differences between CHMMF and VRTX stock?
Key differences: Market Cap ($4.42M vs $112.22B), P/E Ratio (N/A vs 28.8x), Revenue Growth (-0.5% vs 0.1%), Gross Margin (91.3% vs 53.7%).